A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

Published:2002-07-23 Issue:3 Volume:95 Page:581-587
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Weiss Mark A.,Aliff Timothy B.,Tallman Martin S.,Frankel Stanley R.,Kalaycio Matt E.,Maslak Peter G.,Jurcic Joseph G.,Scheinberg David A.,Roma Todd E.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research Hospital

2. Acute Lymphoblastic Leukemia -- Progress in Children, Less in Adults

3. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811

4. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

5. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Photocatalytic Degradation of Cytarabine from Pharmaceutical Wastewaters;Toxics;2024-05-31

2. AraC interacts with p75NTR transmembrane domain to induce cell death of mature neurons;Cell Death & Disease;2023-07-17

3. Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease;Blood Research;2022-05-30

4. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers;Cancers;2021-02-25

5. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment;Advances in Therapy;2020-04-15